Spanish mythology

EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

Retrieved on: 
Wednesday, April 10, 2024
Malignancy, Spanish mythology, State university system, Patient, Sale, Renal cell carcinoma, Clinical trial, Neoplasm, Therapy, Depreciation, HPHA, USD, Marketing, GLP, Health, Research, ATACS, EPO, Immune system, ADC, BLA, ATAC, Food, Biologics license application, Disease, Magenta, Multiple myeloma, AACR, GCC, Annual report, FDA, Diagnosis, EUR, Supervisory board, Accounting, PET, EDT, Spacecraft, Amanitin, European Patent Convention, Patent, Eli Lilly and Company, Binghamton University, Pharmaceutical industry

Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).

Key Points: 
  • Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).
  • As a result, Heidelberg Pharma lost sales revenue in the low single-digit millions for the 2023 financial year.
  • In April 2023, Heidelberg Pharma signed a termination agreement with Magenta under which all licensed ATAC rights and some Magenta patents were assumed by Heidelberg Pharma.
  • The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.

EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Retrieved on: 
Thursday, July 13, 2023
State University of New York, AACR, EAP, GCC, Half-life, HPHA, ATAC, SRC, Binghamton University, Multiple myeloma, Clinical trial, State university system, Bone marrow, Cancer, American Association for Cancer Research, FSE, Magenta, Research, ATACS, Sale, Spanish mythology, Amanitin, Data analysis, CAIX, Patient, Antibody-drug conjugate, Microsoft Access, Marketing, CFO, Management, Ethics, ADC, Eli Lilly and Company, Depreciation, Spacecraft, Phase, FDA, Therapy, Market Access Program, Safety, Disease, Pharmaceutical industry, Vaccine, Fine chemical, Generic drug, Cryptocurrency, Telix, Emergence

Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).

Key Points: 
  • Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).
  • HDP-101 (BCMA-ATAC) program: Heidelberg Pharma presented preliminary safety data from the clinical trial with HDP-101.
  • The Heidelberg Pharma Group (Heidelberg Pharma) – comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The full-year financial guidance issued on 24 March 2023 for the Heidelberg Pharma Group is confirmed at this time.

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Retrieved on: 
Tuesday, March 21, 2023
GMP, Investment, Cohort, Head, Oncology, European Society for Medical Oncology, PRAME, Development, Patient, Corr, Congress, University, Half-life, Gene editing, Uveal melanoma, Research, Spanish mythology, CD8, Wellington Management Company, Entrepreneurship, CD4, IND, Conference, Safety, GSK, European Central Bank, ESMO, Central bank, COL6A3, TCR, Traction, Administration, Science Translational Medicine, Medical sociology, Ovarian cancer, Family, Synovial sarcoma, CRISPR, Doctor of Philosophy, Clinical trial, Bristol Myers Squibb, EUR, State Administrative Expenses, Toxic shock syndrome toxin-1, Bank, LP, Tumor microenvironment, VI, Peptide, Nivolumab, Pharmaceutical industry, Cryptocurrency, Vaccine, Medical imaging

In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.

Key Points: 
  • In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.
  • This allows Immatics to shorten the turnaround time and to provide the cell therapy product candidate to patients faster.
  • In October 2022, GSK provided Immatics with notice of its decision to terminate their collaboration.
  • Immatics successfully completed an underwritten public offering in October 2022, raising approximately $110 million before deducting underwriting discount and offering expenses.

DGAP-News: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure

Retrieved on: 
Tuesday, August 30, 2022
ISIN, Baader Bank AG, Commercial, Multiple myeloma, German Commercial Register, List, EUR, FSE, Mass meeting, Capital, Frankfurt Stock Exchange, Non-Hodgkin lymphoma, BCMA, AFRICA, Spanish mythology, Company, Authorization, HPHA, CD37, Biotechnology, Gesellschaft mit beschränkter Haftung, PSMA, Annual, Security (finance), Fine chemical, EU

Ladenburg, Germany, 30 August 2022 Heidelberg Pharma AG (FSE: HPHA) today successfully completed the capital measure adopted on 12 August 2022 and generates gross issue proceeds of approximately EUR80million by placing all new shares.

Key Points: 
  • Ladenburg, Germany, 30 August 2022 Heidelberg Pharma AG (FSE: HPHA) today successfully completed the capital measure adopted on 12 August 2022 and generates gross issue proceeds of approximately EUR80million by placing all new shares.
  • As part of the capital measure, a total of 12,408,648 new shares at a price of EUR 6.44 each were placed.
  • With the subscription of a total of 11,838,652 shares, Huadong Investment now holds 25% of Heidelberg Pharma shares.
  • Heidelberg Pharma has thus almost completely utilized the Authorized Capital 2020/I available for the issuance of new shares.

DGAP-News: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million

Retrieved on: 
Friday, August 12, 2022
Supervisory board, Regulated market, FSE, BCMA, ISIN, Prospectus, Gesellschaft mit beschränkter Haftung, Financial Oversight and Management Board for Puerto Rico, Frankfurt Stock Exchange, Baader Bank AG, Partnership, AFRICA, PSMA, Multiple myeloma, Federal Financial Supervisory Authority, HPHA, Results of the 2013 German federal election, August Faller GmbH & Co. KG, Spanish mythology, Non-Hodgkin lymphoma, CD37, CEST, Security (finance), Online gambling, Bank, Fine chemical, EU

Ladenburg, Germany, 12 August 2022 The Management Board of Heidelberg Pharma AG (FSE: HPHA) today formally adopted a resolution, with the approval of the Supervisory Board, to conduct a rights issue in the amount of up to EUR80million.

Key Points: 
  • Ladenburg, Germany, 12 August 2022 The Management Board of Heidelberg Pharma AG (FSE: HPHA) today formally adopted a resolution, with the approval of the Supervisory Board, to conduct a rights issue in the amount of up to EUR80million.
  • Heidelberg Pharma will implement the capital measure based on the prospectus and using Authorized Capital 2020/I as of 16August2022.
  • Huadong plans to participate in the rights issue, acquiring up to approximately 26% of the outstanding shares after completion of the rights issue.
  • Heidelberg Pharma AG is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, CEO, Visual impairment, TCF Bank Stadium, Day, Ciclosporin, Patient, DED, Therapy, Duane syndrome, Safety, Pathology, Spanish mythology, Pharmacotherapy, ASCRS, Food, Disease, Pharmaceutical industry, Medical imaging

"This is the first submission of a novel product category of water-free topical drug therapies utilizing EyeSol as a drug carrier", said Christian Roesky, Ph.D., CEO, Novaliq.

Key Points: 
  • "This is the first submission of a novel product category of water-free topical drug therapies utilizing EyeSol as a drug carrier", said Christian Roesky, Ph.D., CEO, Novaliq.
  • "CyclASol is a first-of-a-kind drug therapy and aims to expand treatment success for patients with dry eye disease and their eye care professionals.
  • CyclASol is a first-of-a-kind topical treatment of cyclosporine, a potent anti-inflammatory and selective immunomodulatory drug.
  • 2019; 13:2285-2292
    Dunn JD, Karpecki PM, Meske ME, Reissman D. Evolving knowledge of the unmet needs in dry eye disease.

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, CEO, Visual impairment, TCF Bank Stadium, Day, Ciclosporin, Patient, DED, Therapy, Duane syndrome, Safety, Pathology, Spanish mythology, Pharmacotherapy, ASCRS, Food, Disease, Pharmaceutical industry, Medical imaging

"CyclASol is a first-of-a-kind drug therapy and aims to expand treatment success for patients with dry eye disease and their eye care professionals.

Key Points: 
  • "CyclASol is a first-of-a-kind drug therapy and aims to expand treatment success for patients with dry eye disease and their eye care professionals.
  • CyclASol is a first-of-a-kind topical treatment of cyclosporine, a potent anti-inflammatory and selective immunomodulatory drug.
  • A Water-free 0.1% CyclosporineA Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase II/III ESSENCE Study.
  • A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree CyclosporineFormulation for Treatment of Dry Eye Disease.

Splitit brings its Installments-as-a-Service to the rental market through its partnership with letus

Retrieved on: 
Wednesday, August 3, 2022
SPT, Spanish mythology, API, Turnaround ADR, Installment sale, ASX, Face, Australian Securities Exchange, Ecosystem, CEO, OTCQX, US, Sale, Auction, Lease, Property management, Online shopping

letus (previously RentMoola) is bringing Splitit's installment payment option to its award-winning cloud payment platform for the property rental market.

Key Points: 
  • letus (previously RentMoola) is bringing Splitit's installment payment option to its award-winning cloud payment platform for the property rental market.
  • ATLANTA, August3, 2022 /PRNewswire/ -- Splitit (ASX:SPT, OTCQX:SPTTY) announced letus has selected Splitit to bring its Installments-as-a-Service to its cloud payment platform for the property rental market, allowing tenants to pay expenses in several interest-free installments on their credit card.
  • letus is bringing Splititto its award-winning cloud payment platform for the property rental market.
  • The collaboration brings a first-of-its-kind payment option to letus's award-winning cloud payment platform for property managers and owners.

DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022

Retrieved on: 
Tuesday, July 12, 2022
Income, BCMA, Achievement, AACR, Safety, August Faller GmbH & Co. KG, Federal Ministry of Finance (Germany), Federal Ministry for Economic Affairs and Energy, FSE, Spanish mythology, Telix, Federal Financial Supervisory Authority, Therapy, American Association, ADC, Patient, CEO, Phase, Medicine, Economy, COVID-19, Kidney, Redhill, Multiple myeloma, Federal, Huadong Medicine, HPHA, CFO, Lymphatic system, Depreciation, Association, Gesellschaft mit beschränkter Haftung, Annual general meeting, Partnership, NASDAQ, Security (finance), Fine chemical, Pharmaceutical industry

Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: "We are looking back on an exceptionally successful first half of the year.

Key Points: 
  • Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: "We are looking back on an exceptionally successful first half of the year.
  • The Heidelberg Pharma Group (Heidelberg Pharma) comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH reports consolidated figures.
  • The net loss posted by the Heidelberg Pharma Group for the first six months of 2022 came to EUR8.6 million (previous year: EUR13.1 million).
  • In this respect, the full-year financial guidance issued on 24 March 2022 for the Heidelberg Pharma Group will not be adjusted at this time.

letus Announces Strategic Partnership with MRI Software to Expand Flexible Rent to Commercial and Residential Real Estate

Retrieved on: 
Thursday, June 2, 2022
VP, Time, MRI Software, Software, CEO, Property technology, Partnership, Organization, Solution, Work, Technology, Freedom, Spanish mythology, Financial technology, MRI, Communication, Automation, Property management, Medical imaging, BC

The partnership enables commercial and residential real estate companies to streamline the payments process and offer an innovative, flexible payment experience for customers.

Key Points: 
  • The partnership enables commercial and residential real estate companies to streamline the payments process and offer an innovative, flexible payment experience for customers.
  • "MRI's partnership with letus will give our Canadian community of renters and landlords easier access to a world-class payments platform," shared Sean Slack, VP of Partner Connect at MRI.
  • letus integrates with MRI LivingTM residential management suite and MRI @WorkTM commercial management suite of products to improve the payment experience by reducing manual entry to increase reliability and security.
  • Through innovative solutions and a rich partner ecosystem, MRI gives real estate companies the freedom to realize their vision of building thriving communities and stronger businesses.